![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CRX |
Gene summary for CRX |
![]() |
Gene information | Species | Human | Gene symbol | CRX | Gene ID | 1406 |
Gene name | cone-rod homeobox | |
Gene Alias | CORD2 | |
Cytomap | 19q13.33 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O43186 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1406 | CRX | HCC1 | Human | Liver | HCC | 1.84e-06 | 1.17e+00 | 0.5336 |
1406 | CRX | HCC2 | Human | Liver | HCC | 9.06e-18 | 1.29e+00 | 0.5341 |
1406 | CRX | HCC5 | Human | Liver | HCC | 4.86e-10 | 8.29e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CRX | SNV | Missense_Mutation | c.676N>A | p.Val226Met | p.V226M | O43186 | protein_coding | tolerated(0.19) | benign(0.017) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CRX | SNV | Missense_Mutation | novel | c.449N>T | p.Ser150Leu | p.S150L | O43186 | protein_coding | tolerated(0.5) | benign(0.011) | TCGA-AC-A8OS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CRX | SNV | Missense_Mutation | c.598N>A | p.Ala200Thr | p.A200T | O43186 | protein_coding | tolerated(0.08) | probably_damaging(0.948) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CRX | SNV | Missense_Mutation | rs769355351 | c.664N>A | p.Leu222Ile | p.L222I | O43186 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C8-A12V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CRX | insertion | Frame_Shift_Ins | novel | c.213_214insTGCATAAGAAAGTTTA | p.Val72CysfsTer14 | p.V72Cfs*14 | O43186 | protein_coding | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
CRX | SNV | Missense_Mutation | c.563N>T | p.Ser188Phe | p.S188F | O43186 | protein_coding | tolerated(0.07) | possibly_damaging(0.455) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
CRX | SNV | Missense_Mutation | novel | c.596N>T | p.Ser199Phe | p.S199F | O43186 | protein_coding | deleterious(0.04) | possibly_damaging(0.722) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
CRX | SNV | Missense_Mutation | c.455N>T | p.Ser152Phe | p.S152F | O43186 | protein_coding | tolerated(0.2) | benign(0.227) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
CRX | SNV | Missense_Mutation | c.871N>G | p.Gln291Glu | p.Q291E | O43186 | protein_coding | deleterious(0.03) | possibly_damaging(0.899) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
CRX | SNV | Missense_Mutation | c.763G>A | p.Gly255Ser | p.G255S | O43186 | protein_coding | tolerated(0.6) | benign(0.014) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |